Video

There Are Multiple Dynamic Biomarkers for Bladder Cancer

Author(s):

Padmanee Sharma, M.D., Ph.D.

While there are a few common and well-known checkpoints for bladder cancer, there are also many more than PD-1, PD-L1 and CTLA-4.

When it comes to biomarkers used to determine treatment strategy in bladder cancer, there is more than PD-1, PD-L1 and CTLA-4, says Padmanee Sharma, M.D., Ph.D., Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.

Researchers have not yet examined or reached a full understanding of all the possible checkpoints, especially since the targets — like the immune response in general – are very dynamic and change over time.

Related Videos
Image of a woman with long red hair.
Image of a man in a suit.
Image of woman with brown hair.
Image of a man with short hair, wearing a buttoned-up shirt.
Image of a man with short black hair.
Image of a woman with tied back hair, wearing pearl earrings.
Image of a woman with layered hair, wearing a bright blue cardigan.
Image of a man with short black hair.
Image of man with gray hair.
Related Content
Tranexamic Acid During Radical Cystectomy Does Not Lead to Blood Transfusion Reduction in Bladder Cancer
October 24th 2024

Tranexamic Acid During Radical Cystectomy Does Not Lead to Blood Transfusion Reduction in Bladder Cancer

Ryan Scott
The use of prophylactic tranexamic acid didn't lead to a reduction in blood transfusion for patients undergoing open radical cystectomy for bladder cancer.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
FDA Accepts New Drug Application for UGN-102 in Bladder Cancer
October 17th 2024

FDA Accepts New Drug Application for UGN-102 in Bladder Cancer

Ryan Scott
The FDA has accepted a new drug application for the intravesical solution of UGN-102 in low-grade intermediate-risk non–muscle-invasive bladder cancer.
cancer horizons podcast logo
December 20th 2023

FDA Approves 3 Treatments, Cancer Vaccine Shows Promise

Alex Biese Brielle Benyon
The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.
Illustration of bladder.
October 4th 2024

Opdivo with Abraxane May Expand Therapeutic Opportunities For MIBC

Spencer Feldman
Patients with muscle-invasive bladder cancer experienced safe medical and surgical treatment with the NURE-combo.
Illustration of a bladder in blue.
September 20th 2024

Keytruda Improves Disease-Free Survival in Some With Urothelial Carcinoma

Tony Berberabe, M.P.H.
Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived without signs of cancer.